Technology

IVMED-10 and IVMED-20

The iVeena lead products are IVMED-10 for routine post cataract surgery inflammation and IVMED-20 for more serious forms of post cataract surgery and to prevent Retinal Thickening.

Landscape and Problem:

Cataract surgery is the most common surgical procedure in the US, numbering about 4 million cases in 2014; by 2020 that is expected to rise 5 million. Similarly, global cataract surgery volume is expected to grow from 20 million in 2010 to 32 million in 2020. Patients undergoing cataract extraction are often prescribed 3 different eyedrops at 3 different schedules for 3 different durations, leading to poor compliance which can reduce satisfaction and sometimes compromise or delay visual recovery.

iVeena Technology:

graphic 2 updateB 100915The bioerodible dexamethasone implant (BDI) will enable drop-free cataract surgery by delivering dexamethasone to the front of the eye (treating post-surgical inflammation) and the back of the eye (preventing the complication of cystoid macular edema, which occurs in about 8.2% of patients undergoing routine cataract surgery). This will transform care by transcending the challenges of patient compliance and reducing complications, demands on instruction time on physicians and staff, and improving the experience of recovery from surgery. The BDI drug delivery device is implanted in the lens capsule at the time of surgery (a few seconds required for implantation; no additional procedure required) and releases dexamethasone either over 2 weeks (IVMED-10 for routine cases) or 6 weeks (IVMED-20 for complex cases, such as patients with diabetes or pre-existing inflammation). Its PLGA matrix degrades by hydrolysis shortly thereafter and does not alter the transparency of the intraocular lens as it is peripheral to the lens and does not migrate in the rest of the eye as it is enveloped by the capsule. It is the only drug delivery device to rest within the lens capsule of the eye and, therefore, we believe that it is the only drug delivery device capable of bidirectional drug delivery to both the front and back segments of the eye.

Issued Patent: 8,663,194

Published Articles:
www.ncbi.nlm.nih.gov/pubmed/23321274
www.ncbi.nlm.nih.gov/pubmed/24947436